Danske Bank A S purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 68,561 shares of the medical research company’s stock, valued at approximately $14,532,000. Danske Bank A S owned approximately 0.06% of Quest Diagnostics at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. Key Financial Inc lifted its stake in Quest Diagnostics by 1,728.6% in the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares during the last quarter. Quattro Advisors LLC acquired a new position in shares of Quest Diagnostics during the 4th quarter worth $25,000. DV Equities LLC bought a new position in shares of Quest Diagnostics during the 4th quarter valued at $27,000. Sittner & Nelson LLC acquired a new stake in shares of Quest Diagnostics in the 4th quarter valued at $29,000. Finally, McIlrath & Eck LLC acquired a new stake in shares of Quest Diagnostics in the 4th quarter valued at $32,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Quest Diagnostics
In related news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the transaction, the chief executive officer owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 19,747 shares of company stock valued at $3,947,088. Corporate insiders own 0.88% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on DGX
Quest Diagnostics Price Performance
NYSE DGX opened at $241.80 on Friday. The stock has a 50-day simple moving average of $218.52 and a 200 day simple moving average of $204.87. Quest Diagnostics Incorporated has a twelve month low of $171.18 and a twelve month high of $245.68. The stock has a market capitalization of $26.69 billion, a PE ratio of 25.67, a P/E/G ratio of 2.23 and a beta of 0.56. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59.
Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same period last year, the business posted $2.62 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.
Quest Diagnostics Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is currently 36.52%.
Quest Diagnostics Company Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Featured Articles
- Five stocks we like better than Quest Diagnostics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
